CD19 and B-cell chronic lymphocytic leukemia: Some of them were proved to be successful targets with significant curative effects on some malignant hematological tumors, such as anti-CD19 CAR-T therapy for the treatment of chronic lymphocytic leukemia [61], and anti-CTL019 CAR-T therapy for the treatment of relapsed and refractory B-cell acute lymphoblastic leukemia [62].